GlassScriptPhysician profile
Michelle Gonzalez
NPI 1174729420
$7,860.04
in general payments reported to CMS, 2019-2025
30 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $514 · 2021: $1,039 · 2022: $1,431 · 2023: $1,476 · 2024: $1,232 · 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,172 · Entertainment: $145 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,171.67 |
| Entertainment | $145.49 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,239.44 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $752.82 | 2019-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $604.77 | 2021-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $454.16 | 2022-2025 | Miebo, Xiidra, Infuse |
| Oyster Point Pharma, INC. | $419.18 | 2022-2025 | Tyrvaya |
| Alcon Vision LLC | $369.06 | 2019-2025 | Total30, Hydrus Microstent, Wavelight Ex500 Excimer Laser |
| Allergan, INC. | $368.50 | 2019-2021 | |
| Topcon Healthcare, INC. | $362.26 | 2020-2023 | |
| Glaukos Corporation | $344.90 | 2023-2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Mallinckrodt Hospital Products INC. | $297.11 | 2021-2025 | Acthar |
| Rxsight INC | $285.97 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Sight Sciences, INC. | $273.33 | 2021-2022 | |
| Optos, INC. | $269.43 | 2020-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| New World Medical,INC. | $249.71 | 2023-2025 | Kahook Dual Blade, Streamline, Via360 |
| Horizon Therapeutics Plc | $240.25 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $225.92 | 2019 | |
| Kala Pharmaceuticals, INC. | $147.47 | 2019-2021 | |
| Visionix USA, INC | $141.41 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $135.51 | 2023 | Lipiflow System Activator (Disposable) |
| Maculogix, INC. | $129.36 | 2020 | |
| Eyevance Pharmaceuticals LLC | $103.48 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $79.97 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $67.62 | 2019-2022 | |
| Coopervision INC. | $62.50 | 2023 | Onefit Contact Lens |
| Dompe US, INC. | $60.75 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $60.47 | 2019-2021 | |
| Harrow Eye, LLC | $54.62 | 2024-2025 | Vevye |
| Amgen INC. | $24.06 | 2025 | Tepezza |
| Thea Pharma INC. | $19.51 | 2023 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.